» Authors » Margaret L Lind

Margaret L Lind

Explore the profile of Margaret L Lind including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 202
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Serina P, Stavrand A, Lind M, Gettel C, Southerland L, Goldberg E
J Am Med Dir Assoc . 2024 Jun; 25(8):105056. PMID: 38843872
Critical information gaps exist in nursing home-to-emergency department (NH-ED) transfer documentation. Standardization of forms may address these gaps. In a single state, a Continuity of Care Acute Care Transfer (CoC)...
2.
Lazar Neto F, Hitchings M, Amin A, de Franca G, Lind M, Scaramuzzini Torres M, et al.
Lancet Reg Health Am . 2024 May; 34:100755. PMID: 38737773
Background: The emergence of COVID-19 variants with immune scape and the waning of primary vaccine schemes effectiveness have prompted many countries to indicate first and second booster COVID-19 vaccine doses...
3.
Dorion M, Ticona J, Fofona M, Lind M, Nery N, Victoriano R, et al.
medRxiv . 2023 Dec; PMID: 38076979
Residents of informal urban settlements have a high risk of COVID-19 exposure and have less access to medical care, making vaccine-driven prevention critical in this vulnerable population. Despite robust vaccination...
4.
Lind M, Dorion M, Houde A, Lansing M, Lapidus S, Thomas R, et al.
Nat Commun . 2023 Aug; 14(1):5055. PMID: 37598213
Whether SARS-CoV-2 infection and COVID-19 vaccines confer exposure-dependent ("leaky") protection against infection remains unknown. We examined the effect of prior infection, vaccination, and hybrid immunity on infection risk among residents...
5.
Lind M, Kennedy B, Nieto M, Houde A, Sosensky P, Borg R, et al.
Health Justice . 2023 Mar; 11(1):16. PMID: 36913159
Background: Vaccine hesitancy is common among incarcerated populations and, despite vaccination programs, vaccine acceptance within residents remains low, especially within jails. With the goal of assessing the Connecticut DOC's COVID-19...
6.
Lind M, Robertson A, Silva J, Warner F, Coppi A, Price N, et al.
PLoS Med . 2022 Dec; 19(12):e1004136. PMID: 36454733
Background: The benefit of primary and booster vaccination in people who experienced a prior Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remains unclear. The objective of this study was...
7.
Lind M, Copin R, McCarthy S, Coppi A, Warner F, Ferguson D, et al.
J Infect Dis . 2022 Nov; 227(5):663-674. PMID: 36408616
Background: The impact variant-specific immune evasion and waning protection have on declining coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) remains unclear. Using whole-genome sequencing (WGS), we examined the contribution these...
8.
Ranzani O, Hitchings M, Melo R, de Franca G, Fernandes C, Lind M, et al.
Nat Commun . 2022 Oct; 13(1):5536. PMID: 36202800
The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous...
9.
Hitchings M, Ranzani O, Lind M, Dorion M, DAgostini T, Paula R, et al.
BMJ . 2022 Jun; 377:e070102. PMID: 35697361
Objective: To estimate the change in odds of covid-19 over time following primary series completion of the inactivated whole virus vaccine CoronaVac (Sinovac Biotech) in São Paulo State, Brazil. Design:...
10.
Lind M, Schultes O, Robertson A, Houde A, Cummings D, Ko A, et al.
Clin Infect Dis . 2022 Jun; 76(3):e327-e335. PMID: 35686341
Background: The Centers for Disease Control and Prevention recommends serial rapid antigen assay collection within congregate facilities. Although modeling and observational studies from communities and long-term care facilities have shown...